Pfizer Inc. (NYSE:PFE) announced that its phase 2 randomized study, PALOMA-1, of palbociclib combined with letrozole, achieved its primary endpoint. Pfizer Inc. (NYSE:PFE) shares after opening at $30.99 moved to $31.25 on last trade day and at the end of the day closed at $31.23. Company price to sales ratio in past twelve months was calculated as 3.87 and price to cash ratio as 6.16. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -3.28%.
Merck & Co. (NYSE:MRK)’s experimental hepatitis C pill produced clinical trial results positioning the drug as a strong competitor to a potential blockbuster therapy from Gilead Sciences Inc. (GILD:US)
Merck & Co., Inc. (NYSE:MRK) shares advanced 3.74% in last trading session and ended the day on $57.10. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 26.24%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that it has filed new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for hepatitis C virus (:HCV) candidates, daclatasvir (:DCV) and asunaprevir (:ASV). While daclatasvir belongs to a new class of drugs- NS5A inhibitors- asunaprevir is a NS3 protease inhibitor. Bristol-Myers Squibb Co (NYSE:BMY) shares moved up 3.08% in last trading session and was closed at $50.57, while trading in range of $49.06 – $50.62. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -4.19%.
Eli Lilly and Co. (NYSE:LLY) said its Japanese partner in co-marketing a diabetes drug bears all of the liability for a $9 billion damage order against the two companies by a federal jury. Eli Lilly and Co (NYSE:LLY) weekly performance is 2.16%. On last trading day company shares ended up $60.43. Eli Lilly and Co (NYSE:LLY) distance from 50-day simple moving average (SMA50) is 6.02%. Analysts mean target price for the company is $58.24.
Leave a Reply